eTIL: Enhancing Anti-Tumor Function through CRISPR/Cas9 Gene Editing
Time: 11:00 am
day: Conference Day One - Track A - AM
Details:
- Immune CRISPRomics Platform discovered SOCS1 and Regnase-1 as top gene targets enhancing T-cell anti-tumor function
- KSQ-001EX and KSQ-004EX are single and dual-edited engineered TIL (eTIL) products with inactivation of SOCS1 and Regnase-1
